Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26135935 | 1.00 | KMT2A (0.65) | KMT2AHTTMEN1POLBTDP1 | |
| SCHEMBL26135049 | 1.00 | KMT2A (0.65) | KMT2AHTTMEN1POLBTDP1 | |
| SCHEMBL22892508 | 0.81 | MAPT (0.71) | KMT2AHTTMEN1POLBTDP1 | |
| SCHEMBL8909067 | 0.80 | CTSL (0.52) | KMT2AHTTMEN1POLBTDP1 | |
| SCHEMBL31653615 | 0.79 | MAPT (0.80) | KMT2AHTTMEN1POLBTDP1 | |
| SCHEMBL26135108 | 0.79 | MAPT (0.80) | KMT2AHTTMEN1POLBTDP1 | |
| SCHEMBL26115021 | 0.79 | MAPT (0.80) | KMT2AHTTMEN1POLBTDP1 | |
| SCHEMBL8909361 | 0.78 | CTSS (0.63) | KMT2AHTTMEN1POLBTDP1 | |
| SCHEMBL8908990 | 0.78 | SMN1; SMN2 (0.58) | KMT2AHTTMEN1POLBTDP1 | |
| SCHEMBL22737807 | 0.75 | MAPT (0.68) | KMT2AHTTMEN1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214982-A1 | COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-07-03 | — | — | US | disclosed |
| EP-4499615-A1 | COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY | Ramot at Tel-Aviv University Ltd. (IL) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023187783-A1 | COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214982-A1 | COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY | ATF4, ERN1, ERN2 | KMT2A 4213/4885HTT 3841/4885MEN1 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.